The business combination reinforces Crown's position as a leading, innovative, high-growth aesthetics and skincare company JOHNSON CITY, Tenn., Feb. 6, 2025 /PRNewswire/ ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

First Jointly Developed AI Agent Helps Customers Maximize Cisco Investments and Boosts Productivity   News Summary: Powerful Partnership: The first of several AI agents being developed by Cisco with ...

Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance"), today announced that the tender offer to purchase all of the issued and outstanding shares of common stock ...

Protein disulfide isomerases (PDIs) are essential enzymes that facilitate the proper folding of proteins and maintain protein quality within the endoplasmic reticulum.

As we approach another year of groundbreaking research in cancer care and significant treatment innovations, various companies are taking the ...

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous PolyposisUnderscores unmet need for a ...

VANCOUVER, Washington, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential ...

There was no evidence of clinically significant central adverse events, whereas drowsiness, dry mouth and nausea were reported with comparator agents (levodropropizine, codeine, DL-cloperastine).

Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced the successful closing of its acquisition of Revance Therapeutics, ...

Volume of distribution at steady state (L/kg) 187 194 194 Table 2. Changes in cough-related symptoms following treatment with levocloperastine 30, 60 and 120 mg/day for 6 days in patients with ...